High-affinity TCR for NY-ESO
US12344652B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2017 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | Jan 15, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a T cell receptor (TCR) having a property of binding to a SLLMWITQC (SEQ ID NO: 105)-HLA A2 complex; and the binding affinity of the TCR to the SLLMWITQC (SEQ ID NO: 105)-HLA A2 complex is at least twice that of a wild-type TCR to the SLLMWITQC (SEQ ID NO: 105)-HLA A2 complex. Also provided is a fusion molecule of such a TCR with a therapeutic agent. Such a TCR can be used alone or in combination with a therapeutic agent so as to target tumour cells presenting the SLLMWITQC (SEQ ID NO: 105)-HLA A2 complex.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.